Monocarboxylate transporter 1 inhibitors as potential anticancer agents

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Monocarboxylate transporter 1 (MCT1) plays a crucial role in cancer cell metabolism.
• Developing potent and selective MCT1 inhibitors is a promising therapeutic strategy.

Purpose of the Study:

• To design and synthesize novel α-cyano-4-hydroxycinnamic acid derivatives as MCT1 inhibitors.
• To evaluate the structure-activity relationships (SAR) of these compounds.
• To assess the in vivo efficacy and systemic toxicity of potent MCT1 inhibitors.

Main Methods:

• Synthesis of α-cyano-4-hydroxycinnamic acid derivatives.
• Structure-activity relationship analysis for MCT1 inhibition.
• Systemic toxicity studies in ICR mice.
• In vivo anti-tumor efficacy evaluation in colorectal adenocarcinoma (WiDr) xenograft models in nude mice.

Main Results:

• Optimal inhibitory activity against MCT1 was achieved with specific substitutions (p-N, N-dialkyl/diaryl and o-methoxy groups) on the cyanocinnamic acid template.
• Potent MCT1 inhibitors demonstrated no adverse systemic toxicity, indicated by normal body weight gain in treated mice.
• Compound 27 exhibited significant single-agent activity in inhibiting tumor growth in a colorectal adenocarcinoma xenograft model.

Conclusions:

• Novel MCT1 inhibitors based on the α-cyano-4-hydroxycinnamic acid scaffold were successfully developed.
• Compound 27 shows promising anti-tumor efficacy as a single agent for colorectal cancer treatment.
• Further investigation into MCT1 inhibitors for cancer therapy is warranted.